富罗塞米德在对比诱导性病中的预防性作用 ST段升高心肌梗塞患者接受皮肤冠状动脉干预的患者
Mostafa Ariafar1, Parvin Ghorbani1, Seyed Masoud Seyedian2
1Atherosclerosis Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Advanced biomedical research
|April 11, 2025
概括
在接受初级PCI的ST升高心肌梗塞 (STEMI) 患者中,用罗塞米德治疗后并没有降低对比诱导的脏病 (CIN) 风险. 血尿素含量在富洛塞米德组中较高.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 干预心脏病学 干预心脏病学
背景情况:
- ST升高心肌梗塞 (STEMI) 是一种已知的对比诱导性病 (CIN) 的风险因素.
- 利尿剂正在作为CIN的预防措施进行探索,但它们的有效性仍然不确定.
- 罗西米德对STEMI患者中CIN风险的特定影响需要进一步调查.
研究的目的:
- 为了调查furosemide治疗后是否降低了STEMI患者接受初级皮肤冠状动脉干预 (PCI) 的CIN风险.
主要方法:
- 一项临床试验涉及234名接受初级PCI的STEMI患者.
- 患者被随机分为两组:富洛塞米德治疗 (0.5 mg/kg) 或对照组.
- 在PCI前和之后监测血清肌素和血尿酸 (BUN),以确定CIN.
主要成果:
- 24小时后14.1%的患者和72小时后14.9%的患者出现CIN,两组之间没有显著差异.
- 血尿素 (BUN) 含量在罗塞米德组显著更高 (P < 0.05).
- 富洛塞米德组的男性和吸烟患者比例较高.
结论:
- 低剂量罗西米德与标准水化相结合,与接受初级PCI的STEMI患者中较低的CIN发病率无关.
- 需要对更大的样本进行进一步的研究,以阐明罗西米德在这种患者群体中的作用.
相关概念视频
01:22Heart Failure Drugs: Diuretics
295
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
295
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
321
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
321
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
410
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
410
01:11Renal Failure: Dose Adjustments
37
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
37
01:15Antihypertensive Drugs: Thiazide-Class Diuretics
455
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
455
01:22Heart Failure Drugs: β-Blockers
278
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
278